This blog was written by JC Gutierrez-Ramos, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC.   Despite being central to life on earth, we know little about how microbes interact with each other, their hosts and

CRISPR/Cas genome editing has captured the attention of the popular media, scientific community, and the investment world: the promise of going into a cell and precisely making changes in their genetic code to cure them of illness is certainly captivating.

Jumping into a first-time CEO role in an emerging biotech is a daunting but exciting opportunity – both for the newly-minted chief executive and their Board of Directors. A great hire can be positively catalytic to a startup; and, sadly,

This blog was written by Vanessa King, CEO of Luc Therapeutics, as part of the From The Trenches feature of LifeSciVC Almost 15 years ago – in 2003, to be precise – I was working with genome sequencing pioneer Craig

Startup ecosystems supported by venture capital are defined by dynamism, with the creation, growth, exiting, or failure of new innovative companies conspiring to keep these entrepreneurial landscapes in constant change. Investor returns and sentiment are dramatically impacted by how these

This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Ex-Citigroup CEO Charles Prince famously said in July 2007, regarding Citi’s leveraged lending business, “As long as the music

University tech transfer offices play a central role in the biotech ecosystem, as the successful commercialization of an academic discovery is the aspiration of many young startups. Navigating – and optimizing – this tech transfer process is therefore critical to the

Last week, when the Treasury effectively scuttled the Pfizer-Allergan merger, there was much rejoicing: politicians and pundits alike were thrilled that tax inversion greed had been stopped, and that companies like Pfizer would have to “pay their fair share.”  Investors

This blog was written by Christiana Stamoulis, CFO and Head of Corporate Development at Unum, as part of the “From The Trenches” feature of LifeSciVC. In June 2015 Unum Therapeutics closed a $65M a Series B round, bringing in capital

Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here). This transformative deal is the culmination of over five years of work on

Today we announced the acquisition of Padlock Therapeutics by BMS for up to $600M in total deal value (here), bringing a bittersweet end to a great startup story and the start of a promising and likely productive portfolio for BMS.

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much of the discussion I have had had with my colleagues in publicly traded biotech companies over the last